Transaction value is based on the SEC Form 4 weighted average purchase price ($6.04) as reported for the transaction on October 10, 2025. How does the scale of this transaction compare to Christopher ...

Recursion Pharmaceuticals stock jumped 16% on October 8, 2025, reaching around $6.08 after falling 5.4% the previous day on broader market weakness. The company reported Q2 2025 revenue of $19.2 ...

Article subjects are automatically applied from the ACS Subject Taxonomy and describe the scientific concepts and themes of the article. Nanoparticles and microplastic beads (<5 μm) have been shown to ...

Iran has no immediate plans to resume nuclear talks with European nations after Tehran was hit with snapback sanctions last month, Iran's Foreign Ministry spokesman Esmail Baghaei said on Monday. He ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. This article dives into the happens-before ...

President Donald Trump’s anti-immigration efforts have bumped up against the limits of his “buy American” economic goals. His administration’s detention of hundreds of South Korean Hyundai employees ...

Pull requests help you collaborate on code with other people. As pull requests are created, they’ll appear here in a searchable and filterable list. To get started, you should create a pull request.

Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) shares are volatile on Tuesday following the release of the company’s second-quarter financial results. Here’s what you need to know. RXRX is hovering near ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...